CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today reported financial results for the first quarter ended March 31, 2007.
“We made significant progress this quarter in advancing our product candidate portfolio into later-stage development,” commented Alexis Borisy, President and CEO of CombinatoRx. “We continue to focus our efforts on CRx-102 in rheumatoid arthritis and osteoarthritis and the many other promising programs within the CombinatoRx portfolio. In addition, the phase 2 clinical trial for CRx-150 is now fully enrolled and remains on track to report results late in the second quarter.”
